HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns maintains a Buy rating on Nurix Therapeutics (NASDAQ:NRIX) and raises the price target from $19 to $26.
June 18, 2024 | 10:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Robert Burns maintains a Buy rating on Nurix Therapeutics and raises the price target from $19 to $26.
The Buy rating and increased price target from a reputable analyst can boost investor confidence and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100